Topic: inflammatory bowel disease
Vedanta’s pact with J&J on microbiome therapies has moved to the clinical stage, triggering a $12 million milestone payment.
Fierce 15 winner Jnana Therapeutics has installed co-founder Joanne Kotz, Ph.D., as its new CEO. She has served as president since December 2017.
Scientists at Vanderbilt University found that a glutaminase inhibitor improved the anticancer activity of CAR-T cells.
Some microRNAs could serve as prognostic markers of Crohn's and open the possibility of developing personalized therapies.
Arena Pharma says cannabinoid receptor-targeting olorinab could help treat the pain associated with Crohn’s disease.
A tool called “polygenic risk scoring” could help physicians identify who faces a high risk of serious diseases.
Blocking the signaling receptor NLRP3 could treat a range of autoimmune disorders, IFM researchers believe.
Gossamer Bio netted $230 million in series B, following its $100 million launch in January, to fund immunotherapy trials against undisclosed targets.
IFM Therapeutics is hiving off its NLRP3 stable into a subsidiary dubbed IFM Tre, which expects to advance its lead asset into phase 1 next year.